



DOI: 10.22034/pmj.2022.253554

TGF- β Isoforms and Receptors: A Gene Expression Analysis in Multiple Sclerosis Patients and Normal Individuals

Zeinab Shirvani-Farsani¹, Mehrdad Behmanesh^{2*}, Mohammad Ali Sahraian³

¹Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, IR Iran.

²Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

³ MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

*Corresponding author: Mehrdad Behmanesh, Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Email: behmanesh@modares.ac.ir

Submitted: 2022-04-01

Accepted: 2022-04-28

Keywords:

TGF- β Pathway
TGF- β receptors
Multiple Sclerosis
Personalized Medicine

©2022. Personalized Medicine Journal

Abstract:

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), depicted by lymphocytic infiltration and demyelination. MS is associated with the up-regulation of pro-inflammatory and down-regulation of anti-inflammatory cytokines. The purpose of this experimental study was to evaluate the expression level of TGF- β 1, TGF- β 2, TGF- β -R1, and TGF- β -R2 mRNAs in peripheral blood mononuclear cells (PBMCs) from MS patients and healthy controls using Real-Time PCR. Our findings indicated that the TGF- β -R1 expression level was 2.25 times higher in controls than in MS patients. Also, a significant correlation between normalized expression of TGF- β -R1 and TGF- β 1, or TGF- β 2 was observed. Therefore, these genes could likely play an important role in the etiology of MS.

INTRODUCTION

Multiple sclerosis (MS) is a chronic inflammatory disease, characterized by lymphocytic infiltration and demyelination in the central nervous system (CNS) (1-3). Prognosis, diagnosis, and treatment of this disorder rely upon a greater determination of the mechanisms underlying MS onset and development (4). Inflammatory cascade and the role of different immune cells (including macrophages, natural killer cells, and certain lymphocyte populations) are two considerable factors in the etiology of this disease (5).

In MS dependent inflammatory cascade, various cytokines are up-regulated or down-regulated, including pro-inflammatory (e.g. IFN- γ , TNF- α , and IL-12) and anti-inflammatory (e.g. IL-10) cytokines (6). TGF- β , as one of the most critical anti-inflammatory factors, is secreted not only by the immune cells (mainly macrophages) but also the other non-hematopoietic cells (7). The role of transforming growth factor- β (TGF- β) has been studied in several disorders, particularly in many autoimmune diseases like MS (8-10).

This cytokine is a protein present in three isoforms: TGF- β 1, TGF- β 2, and TGF- β 3 (11). All of the TGF- β

isoforms could participate in the generation of chronic MS lesions (12). Mechanistically, TGF- β signals are generally initiated through binding this factor to the heterodimer complex, composed of type I and II trans-membrane receptor serine/threonine kinase, transforming growth factor- β receptor 1 (TGF- β -R1) and TGF- β -R2 (13). Thus far, several functions have been determined for TGF- β in MS pathogenesis, including 1) suppressing the immune responses, 2) inhibiting T cells, B cells as well as many other cells, 3) inducing the production of regulatory T cells (Treg), 4) repressing leukocyte adhesion to endothelium, 5) down-regulation of adhesion molecules, and 6) sustaining a state of immune tolerance (14, 15).

With regards to the importance of TGF- β 's role in MS pathogenesis, in this experiment, we evaluated the gene expression level of two relevant isoforms (TGF- β 1 and TGF- β 2) as well as receptors (TGF- β -R1 and TGF- β -R2) in peripheral blood mononuclear cells (PBMCs) of MS patients, in comparison with normal individuals. In addition, we investigated the correlation of the gene expressions with the expanded disability status scale (EDSS), the age of onset, or the disease length.

METHODS AND MATERIALS

Patient and control participants

This experimental study was conducted in the genetics Laboratory of Tarbiat Modares University (Tehran, Iran) from 2013-2014. In this research, 61 MS patients and 36 age-, race-, and sex-matched controls were recruited from Multiple Sclerosis centers at Sina Hospital (Tehran, Iran) to investigate the mRNA expression level of TGF- β 1, TGF- β 2, TGF- β -R1, and TGF- β -R2 genes. The patients were diagnosed according to the McDonald criteria. Informed consent was obtained from all human adult participants and the study was approved by the Ethics Committee of Tarbiat Modares University (ethical code: d52/6723).

RNA extraction and cDNA synthesis

After blood collection, PBMC separation was performed using density gradient Ficoll/Paque solution (lymphocyte, Cedarlane, Netherlands) and total RNA was extracted from all patient and control samples, using RNXTM-plus reagent (Cinnagen, Iran) according to the manufacturer's protocol. The samples were subsequently reverse-transcribed into cDNA, using 3 μ g total RNA and 250 μ g oligo dT (MWG, Germany). The reaction was incubated at 70° C for 10 minutes and cooled on ice for 3-5 minutes, followed by adding an RNase inhibitor, 10 mM dNTPs, and Reverse Transcriptase (all from Fermentas, Canada) to 20 ml total volume of the reaction mixture. The mixture was ultimately incubated at 42° C and 80° C for 60-90 and 15 minutes, respectively.

Quantitative reverse transcriptase PCR

cDNA for each sample was used to evaluate the mRNA

expression level of TGF- β 1, TGF- β 2, TGF- β -R1, and TGF- β -R2 genes using relative quantitative reverse transcriptase PCR (qRT-PCR). In this experiment, glyceraldehyde3-phosphate dehydrogenase (GAPDH) was utilized as a housekeeping gene.

Each qRT-PCR reaction was performed in a final volume of 20 μ l, using 10 ng cDNA, 2x SYBR Green I master mix (Takara, Shiga, Japan), and an appropriate primer pair set (Table S1). Thermal condition, as one-step RT-PCR, was carried out by an initial step at 95° C for 15 minutes, followed by 40 cycles at 95° C, 60° C and 72° C for 15 seconds, 30 seconds, and 30 seconds, respectively, in Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, USA). Termed cycle threshold (Ct) was determined for each sample, and the average Ct of duplicate samples was calculated.

STATISTICAL ANALYSIS

Relative quantification data analysis was performed using an arbitrary method (Δ Ct). The significance of differences between control and test groups was determined by an independent t-test using SPSS software (Version 20; SPSS Inc, Chicago, USA) and GraphPad Prism 5 (GraphPad Software, Inc., San Diego, USA). The correlation analysis was assessed by Pearson's correlation coefficient. A P-value of 0.05 was set as a significant threshold.

RESULTS

In this experiment, the age of MS Patients was between 18 and 52 years, with a female to male ratio of 51:10. The control individuals were between 22–45 years of age, with a female to male ratio of 25:11. The demographic characteristics of patients are given in Table 1.




Fig.1 TGF- β -R1 gene expression in PBMCs. A) The mRNA expression of this gene shows a significant increase in the controls compared to MS patients (2.25 times). B) Δ Ct values in the patient and control samples. The results were normalized relative to the level of GAPDH mRNA expression.

Table 1. Demographic and disease characteristics of the MS patients and controls.

	MS Patient	Control
Number	61	31
Age (mean years \pm SD)	32.54 \pm 8.45	29.03 \pm 6.81
RR/SP/PP	55/6/0	-
EDSS (mean \pm SD)	2.45 \pm 1.33	-
Disease Duration	6.42 \pm 3.72	-

Table 2 Correlation between normalized TGF- β 1, TGF- β 2, TGF- β -R1, or TGF- β -R2 expression level in MS patients.

correlation	r	p-value
TGF- β 1-TGF- β 2	0.077	0.551
TGF- β 1-TGF- β RI	0.292	0.023*
TGF- β 1-TGF- β RII	0.164	0.216
TGF- β 2-TGF- β RI	0.477	0.0001***
TGF- β 2-TGF- β RII	0.010	0.9939
TGF- β RI-TGF- β RII	0.194	0.143

*significant p-value < 0.05

***significant p-value < 0.001

Gene expression analyses in MS patients compared to the controls

Findings showed that the TGF- β -R1 mRNA level mean was significantly increased in the PBMCs obtained from the controls compared to MS patients (2.25 times, $p = 0.025$). However, no significant difference was observed for TGF- β 1, TGF- β 2, and TGF- β -R2 mRNA expression levels (Fig. 1).

Analysis of the relationship between the expression levels of genes

We investigated the correlation between mean mRNA levels of the analyzed genes. There was a significant positive association between TGF- β -R1 mRNA level mean and TGF- β 1, or TGF- β 2 in MS patients, but no significant correlation was observed between the other genes' mRNA expression level mean (Table 2).

Moreover, we observed no significant correlation between the normalized expression level of TGF- β 1, TGF- β 2, or TGF- β -R1 genes and disease length, EDSS scores, or age in MS patients. In contrast, data analysis showed a significant positive correlation between TGF- β -R2 mRNA expression level and disease length in MS patients ($r = 0.356$, $p = 0.006$).

DISCUSSION

TGF- β isoforms (TGF- β 1, - β 2, and - β 3) are signaling ligands that promote expression of the extracellular matrix protein components, control growth and differentiation of the epithelial cells and regulate immune cell function. Thus, the study of

the expression of TGF- β isoforms and their receptors may be useful in determining different responses to immunomodulatory as well as combinatory therapies. Moreover, the investigation of TGF- β isoforms offers a model for personalized medicine and precision treatment in patients with different types of cancer and neurodegenerative disorders. Curiously, TGF- β isoforms are important due to their conservation among vertebrates and their different roles in a variety of human diseases including tissue fibrosis, cancer, and MS (15). CNS degeneration and inflammation are important causes of demyelination in MS (16). In 1998, Vincent et al. compared the expression of TGF- β -R1 and TGF- β -R2 by immunohistochemistry in the brain tissue of MS patients and normal controls. They determined that TGF- β isoforms were expressed in microglial cells of the normal individuals' brain tissue. They also demonstrated that the TGF- β isoforms and relevant receptors are expressed in MS lesions (17).

Expression profiling of the MS patients' peripheral blood showed misregulation of SMAD4, SMAD7, and TGF- β -R2. These findings revealed that TGF- β regulation is reduced in MS patients (18). Here, we demonstrated no significant difference in TGF- β 1, TGF- β 2, and TGF- β -R2 mRNA expression levels in the MS patients compared to controls, while TGF- β -R1 expression level was 2.25 times higher in normal subjects compared to the MS patients.

Several investigations have so far represented a difference in TGF- β 1, TGF- β 2, TGF- β -R1, and TGF- β -R2 mRNA levels in vitro and in vivo. TGF- β over-

expression in MS patients, with little disability after thymectomy, disclosed that this protein could have a favorable effect on human diseases with autoimmune backgrounds (19). Press et al. have previously examined glial TGF- β expression of different isoforms in 14 MS patients. Active lesions illustrated TGF- β 2 immuno-reactivity of lesion encircling ramified microglia. On contrary, all three isoforms of this protein were expressed in the astrocytes of active white matter lesions. These results proposed that TGF- β cytokines could be locally expressed in demyelinated cells (20).

Further investigations showed that induction of rTGF- β 1 suppressed IFN- γ , IL-4, IL-6, TNF- α , and perforin up-regulation in MS, but it had no effects on IL-10 or TGF- β expression. The selective prohibitory effects of TGF- β 1 on pro-inflammatory cytokines expression potentially turn it into an attractive treatment for MS disease (21).

MS patients with no or slight disability showed a high level of TGF- β mRNA expression, while moderate or severe disability of MS patients was correlated with a high level of IFN- σ -positive cells. Therefore, TGF- β and IFN- σ could have dissenting effects on MS pathology. Thus, administration of IFN- σ inhibitors and/or TGF- β activators might improve MS disease treatment (22).

These differences between our results and others may be due to environmental factors including Vitamin D (23) or other drugs that patients use. We formerly studied TGF- β 1 expression in 32 patients with MS and 32 healthy controls. Our findings showed no significant change in TGF- β 1 expression in the MS patients compared to the control group (24), suggesting that large sample size could not affect gene regulation level.

Additionally, this study evaluated the correlation between these four gene expressions in MS patients. We detected a positive link only between the expression of TGF- β 1 and TGF- β -R2 as well as the expression of TGF- β 2 and TGF- β -R1 in MS patients; however, there was no significant association between the expressions of other genes. It is proposed that TGF- β -R1 might influence TGF- β 1 and TGF- β 2 expression by phosphorylating the receptor-specific SMADs and promoting a feedback mechanism. Altogether, the expression level of TGF- β -R1 could be considered a risk factor for MS disease which might be associated with inflammatory events in such patients. Investigations have previously implicated that the heterogeneous nature of whole-blood samples may not show the optimal level of gene expressions (25, 26), revealing some limitations in this study. Hence, assessment of gene expression at protein level MS patients' sorted PBMCs could help to better understand the role of TGF- β .

List of abbreviations

MS: Multiple sclerosis
 CNS: central nervous system
 PBMCs: peripheral blood mononuclear cells
 EDSS: expanded disability status scale
 TGF- β : transforming growth factor- β
 TGF- β -R1: transforming growth factor- β receptor 1

Declarations

This study was in accordance with the declaration of Helsinki. This study was approved by the Ethics Committee of Tarbiat Modares University. The informed consent was obtained from all the participants, and informed consent obtained was written.

Consent for publication

Not applicable.

Availability of data and materials

All relevant data are included in the manuscript.

Competing interests

The authors declare that they have no competing interests.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' Contributions

Z.SHF., M.B.; Performed all experiments, analyzed the data and wrote the manuscript. M.A.S.; Contributed to concept and design, manufactured the samples, and final approval of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors gratefully acknowledge contribution of the patients and institutions in this study as well as Roya Amirinejad and Fahimeh Molaahmadi for their valuable laboratory supports. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors, other than Department of Research Affairs of Tarbiat Modares University.

REFERENCES

1. Bhise V, Dhib-Jalbut S: Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. Expert review of clinical immunology 2016, 12(10):1069-1089.
2. Touil H, Kobert A, Lebourrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J et al: Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. Journal of neuroinflammation 2018, 15(1):114.
3. Tian Z, Song Y, Yao Y, Guo J, Gong Z, Wang Z:

- Genetic Etiology Shared by Multiple Sclerosis and Ischemic Stroke. *Frontiers in genetics* 2020, 11:646.
4. Baecher-Allan C, Kaskow BJ, Weiner HL: Multiple Sclerosis: Mechanisms and Immunotherapy. *Neuron* 2018, 97(4):742-768.
 5. Pérez-Cerdá F, Sánchez-Gómez MV, Matute C: The link of inflammation and neurodegeneration in progressive multiple sclerosis. *Multiple Sclerosis and Demyelinating Disorders* 2016, 1(1):9.
 6. Nali LH, Olival GS, Sousa FTG, de Oliveira ACS, Montenegro H, da Silva IT, Dias-Neto E, Naya H, Spangenberg L, Penalva-de-Oliveira AC et al: Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases. *Multiple Sclerosis and Related Disorders* 2020, 44:102243.
 7. Komai T, Inoue M, Okamura T, Morita K, Iwasaki Y, Sumitomo S, Shoda H, Yamamoto K, Fujio K: Transforming Growth Factor- β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals. *Frontiers in Immunology* 2018, 9(1364).
 8. Sanjabi S, Oh SA, Li MO: Regulation of the Immune Response by TGF- β : From Conception to Autoimmunity and Infection. *Cold Spring Harbor Perspectives in Biology* 2017, 9(6).
 9. Lee PW, Severin ME, Lovett-Racke AE: TGF- β regulation of encephalitogenic and regulatory T cells in multiple sclerosis. *European Journal of Immunology* 2017, 47(3):446-453.
 10. Kashima R, Hata A: The role of TGF- β superfamily signaling in neurological disorders. *Acta Biochimica et Biophysica Sinica* 2017, 50(1):106-120.
 11. Voisin A, Damon-Soubeyrand C, Bravard S, Saez F, Drevet JR, Guiton R: Differential expression and localisation of TGF- β isoforms and receptors in the murine epididymis. *Scientific reports* 2020, 10(1):995.
 12. Compston A, Lassmann H, Smith K: Chapter 10 - The neurobiology of multiple sclerosis. In: *McAlpine's Multiple Sclerosis (Fourth Edition)*. Edited by Wekerle ACCLMMNS. Edinburgh: Churchill Livingstone; 2006: 449-490.
 13. Hata A, Chen Y-G: TGF- β Signaling from Receptors to Smads. *Cold Spring Harbor Perspectives in Biology* 2016, 8(9).
 14. Xu J, Wang Y, Jiang H, Sun M, Gao J, Xie A: TGF- β in Mice Ameliorates Experimental Autoimmune Encephalomyelitis in Regulating NK Cell Activity. *Cell transplantation* 2019, 28(9-10):1155-1160.
 15. Nataf S, Guillen M, Pays L: TGF β 1-Mediated Gliosis in Multiple Sclerosis Spinal Cords Is Favored by the Regionalized Expression of HOXA5 and the Age-Dependent Decline in Androgen Receptor Ligands. *Int J Mol Sci* 2019, 20(23).
 16. Zhang X, Hamblin MH, Yin KJ: The long noncoding RNA Malat1: Its physiological and pathophysiological functions. *RNA biology* 2017, 14(12):1705-1714.
 17. Vincent V, Tilders F, Van Dam A: Production, regulation and role of nitric oxide in glial cells. *Mediators of inflammation* 1998, 7(4):239.
 18. Meoli EM, Oh U, Grant CW, Jacobson S: TGF- β signaling is altered in the peripheral blood of subjects with multiple sclerosis. *Journal of neuroimmunology* 2011, 230(1):164-168.
 19. Ateke Mousavi N-k, Abbas M, Abdorreza Naser M, Mohammad Reza S-S, Mohammad Reza E, Maryam S, Mina A, Ali Akbar S-Y: Comparison of Cytokine Expression in Multiple Sclerosis Patients and Healthy Volunteers. *Acta Medica Iranica* 2018, 56(2).
 20. Peress NS, Perillo E, Seidman RJ: Glial transforming growth factor (TGF)- β isotypes in multiple sclerosis: differential glial expression of TGF- β 1, 2 and 3 isotypes in multiple sclerosis. *Journal of neuroimmunology* 1996, 71(1):115-123.
 21. Araujo GR, Aglas L, Vaz ER, Machado Y, Huber S, Himly M, Duschl A, Goulart LR, Ferreira F: TGF β 1 mimetic peptide modulates immune response to grass pollen allergens in mice. *Allergy* 2020, 75(4):882-891.
 22. Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl Å, Link H: Increased transforming growth factor- β , interleukin-4, and interferon- γ in multiple sclerosis. *Annals of neurology* 1994, 36(3):379-386.
 23. Shirvani-Farsani Z, Behmanesh M, Mohammadi SM, Naser Moghadasi A: Vitamin D levels in multiple sclerosis patients: Association with TGF- β 2, TGF- β R1, and TGF- β R2 expression. *Life Sciences* 2015, 134:63-67.
 24. Shirvani-Farsani Z, Behmanesh M, Sahraian MA: Interleukin-10 but not transforming growth factor- β 1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients. *Journal of the Neurological Sciences* 2015, 350(1):18-23.
 25. Pahlevan Kakhki M, Rakhshi N, Heidary M, Behmanesh M, Nikraves A: Expression of suppressor of cytokine signaling 1 (SOCS1) gene dramatically increases in relapsing-remitting multiple sclerosis. *J Neurol Sci* 2015, 350(1-2):40-45.
 26. Heidary M, Rakhshi N, Pahlevan Kakhki M, Behmanesh M, Sanati MH, Sanadgol N, Kamaladini H, Nikraves A: The analysis of correlation between IL-1 β gene expression and genotyping in multiple sclerosis patients. *J Neurol Sci* 2014, 343(1-2):41-45.